BioSpace News Archive

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the fourth quarter and full year 2019.

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a corporate overview at the Cowen & Company 40th Annual Health Care Conference on Monday, March 2nd at 2:50pm ET in New York, NY.

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months and full year ended December 31, 2019.

OPKO Health, Inc. reports business highlights and financial results for the three months ended December 31, 2019..

Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the fourth quarter and full year ending December 31, 2019.

PhaseBio Pharmaceuticals, Inc. announced that Chief Executive Officer Jonathan P. Mow will present a company overview at the Cowen and Company 40th Annual Health Care Conference on Wednesday, March 4, at 10:40 a.m. EST in Boston.

Alimera Sciences, Inc., a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, announced financial results for the three months and year ended December 31, 2019.

Jazz Pharmaceuticals plc announced that the company will webcast its corporate presentations at the following investor conferences

Feb. 26, 2020 13:00 UTC Taiho’s in-licensing facilitates global development and commercialization of zimberelimab as a monotherapy and as a combination backbone for Arcus’s and Taiho’s oncology portfolios Zimberelimab exhibits clinical activity and a safety profile consistent with those of currently approved anti-PD-1 therapies Broad development program delivering randomized data in 2020 for zimberelimab in multiple novel combinations, including with AB154, Arcus’s a

Feb. 26, 2020 13:00 UTC Alnylam Announces Approval in Brazil of ONPATTRO ® for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy − ONPATTRO is the First-Ever RNAi Therapeutic Approved in Latin America – CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Brazilian Health Regulatory Agency (ANVISA) has approved ONPATTRO ® (patisiran) for the treatment of heredita